<DOC>
	<DOCNO>NCT02596243</DOCNO>
	<brief_summary>The purpose study access efficacy safety GX-188E accord protocol patient Cervical Intraepithelial Neoplasia 2 , 2/3 3 ( CIN3 )</brief_summary>
	<brief_title>Phase 2 Clinical Trial Evaluate Safety Efficacy Plasmid DNA Therapeutic Vaccine ( GX-188E )</brief_title>
	<detailed_description>Not provide</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Carcinoma Situ</mesh_term>
	<mesh_term>Cervical Intraepithelial Neoplasia</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1 . Female subject age 1860 year 2 . Histologically confirm HPV16 HPV18 asspcoated CIN2 , CIN 2/3 CIN3 tissue collect less 10 week prior Vaccination/EP # 1 overall lesion size less 50 % cervix area evidence invasive cancer specimen ; 3 . Colposcopy satisfactory base visualization entire squamocolumnar junction upper limit entire acetowhite suspect CIN disease area ; 4 . Healthy subject judge Investigator base medical history , PE , normal result ECG , CBC , Serum Chemistries , CPK urinalysis do 4 week prior enrolment ; 5 . For woman postmenopausal ( least 12 month nontherapy induce amenorrhea ) surgically sterile ( absence ovary and/or uterus ) : agreement remain abstinent use highly effective method contraception treatment period throughout Week 36 response evaluation visit . 6 . Able willing comply study procedure voluntarily sign inform consent form . 1 . Unsatisfactory colposcopy define incomplete visualization entire squamocolumnar junction upper limit entire acetowhite suspect CIN disease area ; 2 . Pregnancy breastfeeding ; 3 . Immunosuppression include concurrent condition require continue use systemic topical steroid near injection site [ deltoid , upper arm ] ( exclude inhale eye dropcontaining corticosteroid ) use immunosuppressive agent . All corticosteroid must discontinue &gt; 4 week prior Day 0 study vaccine administration ; autoimmune disorder , transplant recipient ; 4 . History previous therapeutic HPV vaccination ( individual immunize license prophylactic HPV vaccine ( e.g . Gardasil® , Cervarix® ) exclude ) ; 5 . Positive serological test hepatitis C virus hepatitis B virus surface antigen ( HBsAg ) human immunodeficiency virus ( HIV ) ; 6 . Administration blood product within 3 month enrollment ; 7 . Administration license vaccine within 2 week enrollment ( 4 week measles vaccine ) ; 8 . Participation study investigational compound device within 30 day prior sign informed consent ; 9 . Cardiac preexcitation syndrome ( WolffParkinsonWhite ) ; 10 . History seizure ( unless seizure free 5 year ) ; 11 . Tattoos , scar , active lesions/rashes implantable lead within 3 cm intend site vaccination/EP ; 12 . Any electronic medical implant ( cardiac pacemaker ) ; 13 . Active drug alcohol use dependence , opinion investigator , would interfere adherence study requirement ; 14 . A tendency severe haemorrhage follow acute trauma ; 15 . Prisoners subject compulsorily detain ( involuntarily incarcerate ) treatment either psychiatric physical ( i.e . infection disease ) illness must enrol study ; 16 . Any condition judge investigator would limit evaluation subject .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>CIN2 , CIN2/3 , CIN3</keyword>
	<keyword>Cervical Intraepithelial Neoplasia</keyword>
	<keyword>High-Risk HPV</keyword>
	<keyword>HPV infection</keyword>
	<keyword>precancer Diseases</keyword>
	<keyword>Double Blind</keyword>
	<keyword>Safety/Efficacy</keyword>
</DOC>